Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 13/20 | 0.41 |
| ▸ | MTOR | P42345 | 4/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070216 | 0.89 | RAF1 (0.45) | MAP3K12MTORPIK3CARAF1MAP2K1 | |
| SCHEMBL808106 | 0.88 | MTOR (0.39) | MAP3K12MTORPIK3CATLR9TLR8 | |
| SCHEMBL10070655 | 0.84 | MTOR (0.47) | MAP3K12MTORPIK3CAMAP4K4 | |
| SCHEMBL10069679 | 0.84 | MAP3K12 (0.46) | MAP3K12MTORPIK3CA | |
| SCHEMBL10070657 | 0.83 | PIK3CA (0.42) | MAP3K12MTORPIK3CAMAP4K4 | |
| SCHEMBL15133591 | 0.82 | PIK3CA (0.51) | MAP3K12MTORPIK3CAMAP4K4 | |
| SCHEMBL808263 | 0.81 | GRIN2B (0.41) | MAP3K12MTORPIK3CAMAP4K4 | |
| SCHEMBL808268 | 0.81 | PIK3CA (0.51) | MAP3K12MTORPIK3CAMAP4K4 | |
| SCHEMBL10069681 | 0.81 | JAK1 (0.46) | MAP3K12MTORPIK3CAMAP4K4 | |
| SCHEMBL807834 | 0.81 | MTOR (0.51) | MAP3K12MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | FARS2, TIAL1, DHFR | MAP3K12 4755/4885MTOR 4193/4885PIK3CA 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.